Live Breaking News & Updates on ஜெஃப்ரி ஹவுஸ்ஃபெல்ட்
Stay updated with breaking news from ஜெஃப்ரி ஹவுஸ்ஃபெல்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar Share Article BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. BioFactura Given the prevalence and impact of autoimmune diseases on people across the globe, it is exciting to be taking the next step forward to making a positive impact on these patients’ lives. - Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer of BioFactura, Inc. ....
BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar ibtimes.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com.au Daily Mail and Mail on Sunday newspapers.
BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic Share Article Confirms BARDA support of critical medical countermeasure development Dr. Darryl Sampey, President and CEO of BioFactura, stated, “Funding of our first option confirms the commitment of BARDA to support development of this important product. We look forward to continuing our close collaboration with BARDA as we move into the pathway to FDA approval. FREDERICK, Md. (PRWEB) February 19, 2021 BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at up to $67.4 million for the advanced development of a smallpox biodefense t ....